川芎嗪與復方丹參治療冠心病心絞痛90例療效對比分析

[摘要] 目的 對比川芎嗪與復方丹參治療冠心病心絞痛的療效，以供臨床參考。 方法 以2010年4月～2012年3月在筆者所在醫院接受治療的冠心病心絞痛患者90例為研究對象，進行隨機分組。對照組給予川芎嗪靜脈注射，觀察組給予復方丹參靜脈注射。觀察兩組患者臨床療效和不良反應的差異。 結果 與治療前相比較，兩組患者均取得了一定的療效，其中觀察組總有效率較高，差異有統計學意義（P<0.05）。兩組治療期間均未見明顯的不良反應，差異無統計學意義（P>0.05）。 結論 采用川芎嗪與復方丹參治療冠心病心絞痛均具有良好的有效性和安全性，其中復方丹參的臨床療效更為滿意，對患者的康復具有積極的促進作用。

[關鍵詞] 川芎嗪；復方丹參；心絞痛

[中圖分類號] R541.4 [文獻標識碼] B [文章編號] 2095-0616（2012）22-68-02

Effects analysis of tetramethylpyrazine and compound Danshen in the treatment of angina pectoris on 90 cases

WU Chunjie1 LIU Lin2

1. Department of Medicine， Ping'an Center Community Hospital of Shulan City， Shulan 132605，China；2. Department of Laboratory， General Hospital of Fushun Mining Bureau， Fushun 113008，China

[Abstract] Objective To compare the clinical effect of tetramethylpyrazine and compound Danshen in the treatment of angina pectoris， for clinical reference. Methods 90 cases with angina pectoris in the author's hospital from April 2010 to March 2012 were selected as subjects， and randomly divided into two groups. The control group was treated by tetramethylpyrazine intravenous，and the observation group was treated by compound Danshen.To observe the clinical efficacy and adverse reactions of the two groups. Results Compared with before the treatments， the two groups all got a better efficacy.The total effective rate of the observation group was higher， there had significant statistical difference（P<0.05）.During the treatment，the two groups both had no significant adverse reactions， had no statistically differenc（P>0.05）. Conclusion Tetramethylpyrazine and compound Danshen in the treatment of angina pectoris have good efficacy and safety. The clinical efficacy of compound Danshen is more satisfied， and it has a positive role in promoting the rehabilitation of patients.

[Key words] Tetramethylpyrazine；Compound Danshen；Angina pectoris

冠心病心絞痛是急性冠脈綜合征的常見類型，患者冠狀動脈粥樣硬化斑塊破裂，引起局部心肌缺血加重，如不及時采取措施處理，可引起惡性心律失常、猝死等嚴重后果[1]。筆者對比了川芎嗪與復方丹參治療冠心病心絞痛的有效性和安全性，旨在為臨床合理用藥提供參考，現報道如下。

1 資料與方法

1.1 一般資料

選擇2010年4月～2012年3月在筆者所在醫院接受治療的冠心病心絞痛患者90例為研究對象，均符合中華醫學會心血管病學分會《不穩定性心絞痛和非ST段抬高心肌梗死診斷與治療指南》的診斷標準[2]，并經心電圖檢查確診。將所有患者進行隨機分組，對照組45例，男25例，女20例；年齡42～74歲，平均（60.24±6.35）歲；……